Ad hoc Press Release
Zug, February 21, 2012
Portfolio company Enanta enters into strategic collaboration with Novartis
Private Equity Holding AG (PEH) is pleased to inform that portfolio company Enanta Pharmaceuticals (Enanta) has entered into a strategic collaboration with Novartis for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. PEH is a minority shareholder (<10%) and invested in Enanta in 1999 as part of the original shareholder syndicate.
For more information on the strategic collaboration with Novartis and Enanta, please refer to http://www.enanta.com/pr_022112.html or http://www.enanta.com.
***
Private Equity Holding AG (SIX: PEHN), managed by Alpha Associates, offers investors the opportunity to invest, within a simple legal and tax optimized structure, in a broadly diversified and professionally managed private equity portfolio.
For further information, please contact:
Peter Wolfers, Investor Relations, peter.wolfers@peh.ch, phone +41 41 726 79 80 or http://www.peh.ch.